⌘K
Loading ticker…
As of 2026-08-24, Apimeds Pharmaceuticals US, Inc. (APUS) has a 3-month relative strength percentile of 3 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 26. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 21.0%, relative volume 0.09×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
APUS is in a stage 4 downtrend, week 8. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -32.2% / -69.0%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
APUS appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $63K notional.
Held by 1 ETFs · $63K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $63K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | APUS Jan avg: 12.80% median: 12.80% win: 100% σ: 0.00% n: 1 2025-05-12 → 2026-07-31 | APUS Feb avg: -26.49% median: -26.49% win: 0% σ: 0.00% n: 1 2025-05-12 → 2026-07-31 | APUS Mar avg: 31.57% median: 31.57% win: 100% σ: 0.00% n: 1 2025-05-12 → 2026-07-31 | APUS Apr avg: 5.06% median: 5.06% win: 100% σ: 0.00% n: 1 2025-05-12 → 2026-07-31 | APUS May avg: -22.73% median: -22.73% win: 0% σ: 3.21% n: 2 2025-05-12 → 2026-07-31 | APUS Jun avg: -17.80% median: -17.80% win: 50% σ: 25.98% n: 2 2025-05-12 → 2026-07-31 | APUS Jul avg: -21.96% median: -21.96% win: 0% σ: 29.45% n: 2 2025-05-12 → 2026-07-31 | APUS Aug avg: 5.17% median: 5.17% win: 100% σ: 0.00% n: 1 2025-05-12 → 2026-07-31 (current) | APUS Sep avg: -2.73% median: -2.73% win: 0% σ: 0.00% n: 1 2025-05-12 → 2026-07-31 | APUS Oct avg: 23.03% median: 23.03% win: 100% σ: 0.00% n: 1 2025-05-12 → 2026-07-31 | APUS Nov avg: 32.42% median: 32.42% win: 100% σ: 0.00% n: 1 2025-05-12 → 2026-07-31 | APUS Dec avg: -43.45% median: -43.45% win: 0% σ: 0.00% n: 1 2025-05-12 → 2026-07-31 |